All In Biotech

Drug Trial Radar · NCT06655883

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 9, 2025

Primary completion

Jun 24, 2027

Study completion Jun 24, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with opioid use disorder (OUD) can have trouble falling or staying asleep. Researchers want to know if suvorexant will help people with OUD fall asleep and stay asleep. The goal of this study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.

Conditions

  • Insomnia

Interventions

  • SuvorexantDrug

    Oral Tablet

  • PlaceboDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Sleep Time at Week 8Time frame: Baseline and Week 8
  2. Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 10 weeks
  3. Number of Participants Who Experience One or More Serious Adverse Events (SAEs)Time frame: Up to approximately 10 weeks
  4. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 8 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Cenexel CNS ( Site 2012)

    Garden Grove, California · Recruiting

  • Yale University School of Medicine ( Site 1003)

    New Haven, Connecticut · Recruiting

  • Bradenton Research Center ( Site 2021)

    Bradenton, Florida · Recruiting

  • CenExel iResearch, LLC ( Site 2010)

    Savannah, Georgia · Recruiting

  • Johns Hopkins University ( Site 1001)

    Baltimore, Maryland · Recruiting

  • Hassman Research Institute Marlton Site ( Site 2005)

    Marlton, New Jersey · Recruiting

  • The Rivus Wellness & Research Institute ( Site 2014)

    Oklahoma City, Oklahoma · Recruiting

  • Penn Medicine University of Pennsylvania Health System- Center for Studies of Addiction ( Site 1006)

    Philadelphia, Pennsylvania · Recruiting

  • Butler Hospital ( Site 1002)

    Providence, Rhode Island · Recruiting

  • Medical University of South Carolina ( Site 1005)

    Charleston, South Carolina · Recruiting

  • Adams Clinical Dallas ( Site 2007)

    DeSoto, Texas · Recruiting

  • Memorial Hermann Village ( Site 2001)

    Houston, Texas · Recruiting

  • VCU Institute for Drug and Alcohol Studies ( Site 1004)

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.